Innate Pharma Showcases Encouraging Phase 2 IPH5201 Lung Cancer Data at AACR 2026

Innate Pharma SA ( (FR:IPH) ) has issued an announcement.

On April 17, 2026, Innate Pharma announced that interim Phase 2 results from its MATISSE trial of IPH5201 in resectable non-small cell lung cancer will be showcased in a Clinical Trials Plenary Session at the AACR Annual Meeting 2026. The study evaluates perioperative IPH5201, a first-in-class anti-CD39 antibody, in combination with durvalumab and platinum-based chemotherapy in previously untreated patients.

The pre-planned interim analysis of 40 patients showed that adding IPH5201 to durvalumab and chemotherapy yielded higher pathological complete response rates than the benchmark for durvalumab plus chemotherapy alone. Pathological complete response reached 35.7% in tumors with PD-L1 expression of at least 1% and 50% in tumors with PD-L1 expression of at least 50%, prompting continued recruitment of patients with PD-L1-positive disease in this single-arm trial.

These early data support Innate Pharma’s strategy of targeting the adenosine pathway via CD39 inhibition to enhance anti-tumor immunity in early-stage lung cancer. The prominence of the AACR plenary presentation and the collaboration with AstraZeneca on IPH5201 underscore the company’s bid to strengthen its position in immuno-oncology and could have implications for future regulatory and partnering discussions if the final MATISSE results confirm the interim signal.

The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR3.10 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.

More about Innate Pharma SA

Innate Pharma S.A. is a global clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. Leveraging antibody engineering and innovative target identification, it is advancing a portfolio of potential first- or best-in-class antibody-based therapeutics for solid and hematologic tumors, in collaboration with partners including AstraZeneca and Sanofi.

Headquartered in Marseille, France, with a U.S. office in Rockville, Maryland, Innate Pharma is listed on Euronext Paris and Nasdaq. Its pipeline includes the Nectin‑4 antibody-drug conjugate IPH4502, the anti-KIR3DL2 antibody lacutamab, and the anti-NKG2A antibody monalizumab, targeting areas of high unmet medical need in oncology.

Average Trading Volume: 214,970

Technical Sentiment Signal: Sell

Current Market Cap: €132.3M

For an in-depth examination of IPH stock, go to TipRanks’ Overview page.